23/09/2026 Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy Immunovant’s IMVT-1402 failed to meet the primary endpoint in CLE Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy (Ref) Roche reported positive prespecified interim results from Ph3 IMAgINATION study of sefaxersen (ASO targeting complement factor B) in adults with primary IgA nephropathy (IgAN). The trial met its primary endpoint, demonstrating statistically significant

02/04/2026 Immunovant announced Phase 3 results for batoclimab in thyroid eye disease Immunovant announced Phase 3 results for batoclimab in thyroid eye disease ( Ref ) Immunovant announced topline results from its two Phase 3 (GO) studies that evaluated batoclimab (an FcRn antagonist) for the treatment of adult patients with active, moderate-to-severe thyroid eye disease (TED) The studies failed to meet their primary endpoint of achieving ≥2mm proptosis responder rate at We